The Role of the Gut Microbiome in Immune Dysregulation and Pathogenesis of Inflammatory Bowel Disease
Microbial Dysbiosis in Inflammatory Bowel Disease
DOI:
https://doi.org/10.69750/dmls.02.01.089Keywords:
Gut microbiome, Inflammatory Bowel Disease (IBD), Dysbiosis, Fecal microbiota transplantation (FMT), Immune modulationAbstract
Background: Inflammatory Bowel Disease (IBD), encompassing Crohn's Disease (CD) and Ulcerative Colitis (UC), is a chronic, debilitating disorder affecting the gastrointestinal tract. The gut microbiome is pivotal in maintaining intestinal homeostasis and regulating immune function. Dysbiosis, or microbial imbalance, has been increasingly recognized as a key factor in the pathogenesis of IBD, driving chronic inflammation and immune dysregulation.
Objectives: This systematic review aims to explore the relationship between the gut microbiome and immune responses in IBD. Specifically, it investigates how dysbiosis contributes to disease pathogenesis and immune modulation, and evaluates the efficacy of microbiome-targeted therapies such as probiotics, prebiotics, and fecal microbiota transplantation (FMT).
Methods: We conducted a comprehensive search of PubMed, Scopus, and Web of Science for studies published between 2000 and 2024. Studies included randomized controlled trials, observational studies, and systematic reviews focused on microbial alterations in IBD and the use of microbiome-targeted interventions. Quality was assessed using the Cochrane Risk of Bias Tool and Newcastle-Ottawa Scale. Data synthesis was performed using narrative analysis and descriptive statistics.
Results: Key findings indicate that microbial dysbiosis in IBD is marked by a reduction in beneficial taxa such as Faecalibacterium prausnitzii and Akkermansia muciniphila, alongside the overgrowth of pathogenic microbes like Escherichia coli (AIEC). Microbiome-targeted therapies, including probiotics, prebiotics, and FMT, showed promising results in restoring microbial balance, though efficacy was variable, particularly between UC and CD.
Conclusion: Dysbiosis is central to IBD pathogenesis. Microbiome-targeted therapies offer potential but require personalized approaches to improve treatment efficacy. Future research should integrate multi-omics technologies for better understanding and management of IBD.
Downloads
References
Wang X, Peng J, Cai P, Xia Y, Yi C, Shang A, et al. The emerging role of the gut microbiota and its application in inflammatory bowel disease. Biomedicine & Pharmacotherapy. 2024;179:117302.doi:10.1016/j.biopha.2024.117302
Qiu P, Ishimoto T, Fu L, Zhang J, Zhang Z, Liu Y. The Gut Microbiota in Inflammatory Bowel Disease. Frontiers in Cellular and Infection Microbiology. 2022;12.doi: 10.3389/fcimb.2022.733992
El-Sayed A, Kapila D, Taha RSI, El-Sayed S, Mahen MRA, Taha R, et al. The Role of the Gut Microbiome in Inflammatory Bowel Disease: The Middle East Perspective. J Pers Med. 2024;14(6).doi: 10.3390/jpm14060652
Shan Y, Lee M, Chang EB. The Gut Microbiome and Inflammatory Bowel Diseases. Annu Rev Med. 2022;73:455-68.doi: 10.1146/annurev-med-042320-021020
Gyriki D, Nikolaidis C, Stavropoulou E, Bezirtzoglou I, Tsigalou C, Vradelis S, et al. Exploring the Gut Microbiome’s Role in Inflammatory Bowel Disease: Insights and Interventions. Journal of Personalized Medicine [Internet]. 2024; 14(5).doi: 10.3390/jpm14050507
Maciel-Fiuza MF, Muller GC, Campos DMS, do Socorro Silva Costa P, Peruzzo J, Bonamigo RR, et al. Role of gut microbiota in infectious and inflammatory diseases. Frontiers in Microbiology. 2023;14.doi: 10.3389/fmicb.2023.1098386
Garavaglia B, Vallino L, Amoruso A, Pane M, Ferraresi A, Isidoro C. The role of gut microbiota, immune system, and autophagy in the pathogenesis of inflammatory bowel disease: Molecular mechanisms and therapeutic approaches. Aspects of Molecular Medicine. 2024;4:100056.doi:10.1016/j.amolm.2024.100056
Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease. Cell Research. 2020;30(6):492-506.doi: 10.1038/s41422-020-0332-7
Choden T, Cohen NA. The gut microbiome and the immune system. Exploration of Medicine. 2022;3(3):219-33.doi: 10.37349/emed.2022.00087
Haneishi Y, Furuya Y, Hasegawa M, Picarelli A, Rossi M, Miyamoto J. Inflammatory Bowel Diseases and Gut Microbiota. International Journal of Molecular Sciences [Internet]. 2023; 24(4).doi: 10.3390/ijms24043817
Li Z, Xiong W, Liang Z, Wang J, Zeng Z, Kołat D, et al. Critical role of the gut microbiota in immune responses and cancer immunotherapy. Journal of Hematology & Oncology. 2024;17(1):33.doi: 10.1186/s13045-024-01541-w
Hart AL, Hendy P. The microbiome in inflammatory bowel disease and its modulation as a therapeutic manoeuvre. Proceedings of the Nutrition Society. 2014;73(4):452-6.doi: 10.1017/S0029665114001153
Nishida A, Inoue R, Inatomi O, Bamba S, Naito Y, Andoh A. Gut microbiota in the pathogenesis of inflammatory bowel disease. Clinical Journal of Gastroenterology. 2018;11(1):1-10.doi: 10.1007/s12328-017-0813-5
Celiberto LS, Graef FA, Healey GR, Bosman ES, Jacobson K, Sly LM, et al. Inflammatory bowel disease and immunonutrition: novel therapeutic approaches through modulation of diet and the gut microbiome. Immunology. 2018;155(1):36-52.doi:10.1111/imm.1293 9
Joo M, Nam S. Adolescent gut microbiome imbalance and its association with immune response in inflammatory bowel diseases and obesity. BMC Microbiology. 2024;24(1):268.doi: 10.1186/s12866-024-03425-y
Gowen R, Gamal A, Di Martino L, McCormick TS, Ghannoum MA. Modulating the Microbiome for Crohn’s Disease Treatment. Gastroenterology. 2023;164(5):828-40.doi: 10.1053/j.gastro.2023.01.017
Chen Y, Wang Z, Chen X, Chao G, Zhang S. The role of gut microbiota and metabolites in regulating the immune response in drug-induced enteritis. Journal of Applied Microbiology. 2023;134(3):lxad032.doi: 10.1093/jambio/lxad032
Glassner KL, Abraham BP, Quigley EMM. The microbiome and inflammatory bowel disease. Journal of Allergy and Clinical Immunology. 2020;145(1):16-27.doi: 10.1016/j.jaci.2019.11.003
Bernstein CN, Forbes JD. Gut Microbiome in Inflammatory Bowel Disease and Other Chronic Immune-Mediated Inflammatory Diseases. Inflammatory Intestinal Diseases. 2017;2(2):116-23.doi: 10.1159/000481401
Liu S, Zhao W, Lan P, Mou X. The microbiome in inflammatory bowel diseases: from pathogenesis to therapy. Protein & Cell. 2021;12(5):331-45.doi: 10.1007/s13238-020-00745-3
Hou K, Wu Z-X, Chen X-Y, Wang J-Q, Zhang D, Xiao C, et al. Microbiota in health and diseases. Signal Transduction and Targeted Therapy. 2022;7(1):135.doi: 10.1038/s41392-022-00974-4
Yeoh YK, Zuo T, Lui GC-Y, Zhang F, Liu Q, Li AYL, et al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut. 2021;70(4):698.doi: 10.1136/gutjnl-2020-323020
Huttenhower C, Kostic Aleksandar D, Xavier Ramnik J. Inflammatory Bowel Disease as a Model for Translating the Microbiome. Immunity. 2014;40(6):843-54.doi: 10.1016/j.immuni.2014.05.013
Facciotti F. Modulation of intestinal immune cell responses by eubiotic or dysbiotic microbiota in inflammatory bowel diseases. PharmaNutrition. 2022;21:100303.doi: 10.1016/j.phanu.2022.100303
Downloads
PlumX Metrics
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
©The Author(s) . Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/public domain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
